What is the performance of the Aspartate Aminotransferase to platelets Ratio Index in patients With Chronic Liver Disease? by Zarski, Jean Pierre
KOWSAR
Journal home page: www.HepatMon.com
What is the performance of the Aspartate Aminotransferase to platelets 
Ratio Index in patients With Chronic Liver Disease?
  Jean pierre Zarski 1*
1 Department of Hepatology and Gastroenterology, Digi-DUne Research Center, Grenoble University Hospital, Medical officer of the pole, Grenoble, France
Hepat Mon.2011;11(12):1000-1001. DoI: 10.5812/kowsar.1735143X.798
ARTICLE INFO
Article history:
Received: 27 Mar 2011
Revised: 13 Dec 2011
Accepted: 24 Dec 2011
Keywords:
  Aspartate Aminotransferase
  End Stage Liver Disease
Article type:
Letter to Editor     
  Please cite this paper as: 
Zarski1 Jp, What is the performance of the Aspartate Aminotransfer-
ase to platelets Ratio Index in patients With Chronic Liver Disease? 
Hepat Mon. 2011;11(12):1000-1. DoI: 10.5812/kowsar.1735143X.798
Dear Editor, 
At present, liver biopsy is still the standard in assess-
ing liver fibrosis, especially in patients with chronic viral 
hepatitis. However, biopsy is invasive and carries the risk 
of serious complications. In addition, the accuracy of liv-
er biopsy is limited as a result of intra- and interobserver 
variability and sampling error. Several noninvasive di-
rect and indirect serum markers (such as Fibrotest®, Fi-
brometer®, and Hepascore®) have been developed and 
proposed for the noninvasive prediction of significant 
fibrosis and cirrhosis, especially in patients with chronic 
hepatitis C (1). These methods have been validated in na-
ïve patients with chronic hepatitis C but have been pro-
posed for the diagnosis of liver fibrosis in chronic hepati-
tis B, alcohol cirrhosis, and nASH. 
Another  index  is  the  aspartate  aminotransferase  to 
platelet radio index (ApRI), which has been reported to 
identify patients with hepatic fibrosis and cirrhosis (2). 
The retrospective study by Yilmaz et al. (3) assesses the 
diagnostic  ability  of  the  ApRI  with  207  patients  with 
chronic hepatitis B, 108 with chronic hepatitis C, and 140 
with nAFLD. Receiving operating characteristics (RoC) 
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curves were used. The results showed that the ApRI was 
significantly associated with fibrosis scores in patients 
with chronic hepatitis C and nAFLD but not in those with 
chronic hepatitis B. In patients with chronic hepatitis 
C, the ApRI showed a sensitivity of 72.7%, a specificity of 
62.4% for diagnosis of fibrosis, and an AURoC of 0.582. In 
the nAFLD group, the AURoC was greater than or equal 
to 0.627, but in patients with chronic hepatitis B, the AU-
RoC was less than or equal to 0.541.
These results are different from those observed in a re-
cent metaanalysis published by Lin et al. (4). In this meta-
analysis, 40 studies with a total of 8,739 patients were 
reviewed.  The  AURoCs  of  the  ApRI  for  diagnosing  sig-
nificant fibrosis, severe fibrosis, and cirrhosis were 0.77, 
0.80, and 0.83, respectively. The differences observed be-
tween Lin et al.’s metaanalysis (4) and this study (3) are 
probably due to spectrum bias and a lack of potency. In 
addition, the variations observed between the AURoCs of 
chronic hepatitis C and B patients for the different blood 
tests have been previously published for all scores and 
could be due to a different distribution of fibrosis in the 
two liver diseases, especially the greater perisinusoidal 
fibrosis usually observed with chronic hepatitis C than 
with chronic hepatitis B. In a recent study that compared 
Fibrotest®, Fibrometer®, and Hepascore®, we observed 
that the cutoffs could be different and usually lower in 
patients with chronic hepatitis B than in patients with 
chronic hepatitis C. This study seems to confirm that we 1001 Performance of the Aspartate Aminotransferase to Platelets? Zarski1 JP et al.
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cannot use blood with the main cutoff in both types of 
viral chronic hepatitis. This recent study suggest that the 
ApRI can identify hepatitis C and nAFLD-related fibrosis 
with a moderate degree of accuracy, although not as well 
as Fibrotest®, Fibrotest® and Hepascore®. However, this 
blood test is cheap and easy to perform and may decrease 
the need for taking liver-biopsy specimens among chron-
ic hepatitis C and nAFLD patients. 
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